If you have been reading about regulatory status and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-12-01. Numbers and descriptions here follow the published literature rather than marketing material.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Spectroscopy techniques are useful when the sample being tested is pure, or a very common mixture. When an unknown mixture is being analyzed it must be broken down into its individual parts. Chromatography techniques can be used to break apart mixtures into their components allowing for each part to be analyzed separately. Thin layer chromatography (TLC) is a quick alternative to more complex chromatography methods. TLC can be used to analyze inks and dyes by extracting the individual components. This can be used to investigate notes or fibers left at the scene since each company's product is slightly different and those differences can be seen with TLC. The only limiting factor with TLC analysis is the necessity for the components to be soluble in whatever solution is used to carry the components up the analysis plate. This solution is called the mobile phase. The forensic chemist can compare unknowns with known standards by looking at the distance each component travelled. This distance, when compared to the starting point, is known as the retention factor (Rf) for each extracted component. If each Rf value matches a known sample, that is an indication of the unknown's identity. High-performance liquid chromatography (HPLC) can be used to extract individual components from a mixture dissolved in a solution. HPLC is used for nonvolatile mixtures that would not be suitable for gas chromatography.
The prime recovery ship was USS Wasp. The recovery was supported by 10,249 U.S. Department of Defense personnel, 134 aircraft, and 26 ships. Postflight medical examination found the astronauts to be in good health, and no significant physiological changes were found.
== Safety == The safety of ketosis from low-carbohydrate diets is often called into question by clinicians, researchers and the media. A common safety concern stems from the misunderstanding of the difference between physiological ketosis and pathologic ketoacidosis. There is also continued debate whether chronic ketosis is a healthy state or a stressor to be avoided. Some argue that humans evolved to avoid ketosis and should not be in ketosis long-term. The counter-argument is that there is no physiological requirement for dietary carbohydrates, as adequate energy can be made via gluconeogenesis and ketogenesis indefinitely. Alternatively, the switching between a ketotic and fed state has been proposed to have beneficial effects on metabolic and neurologic health. The effects of sustaining ketosis for up to two years are known from studies of people following a strict ketogenic diet for epilepsy or type 2 diabetes; these include short-term adverse effects leading to potential long-term ones. However, literature on longer term effects of intermittent ketosis is lacking.
Sources: en.wikipedia.org
== Biosynthesis == Epothilone B is a 16-membered polyketide macrolactone with a methylthiazole group connected to the macrocycle by an olefinic bond. The polyketide backbone was synthesized by type I polyketide synthase (PKS) and the thiazole ring was derived from a cysteine incorporated by a nonribosomal peptide synthetase (NRPS). In this biosynthesis, both PKS and NRPS use carrier proteins, which have been post-translationally modified by phosphopantetheine groups, to join the growing chain. PKS uses coenzyme-A thioester to catalyze the reaction and modify the substrates by selectively reducing the β carbonyl to the hydroxyl (Ketoreductase, KR), the alkene (Dehydratase, DH), and the alkane (Enoyl Reductase, ER). PKS-I can also methylate the α carbon of the substrate. NRPS, on the other hand, uses amino acids activated on the enzyme as aminoacyl adenylates. Unlike PKS, epimerization, N-methylation, and heterocycle formation occurs in the NRPS enzyme.
Four classes of mutations are (1) spontaneous mutations (molecular decay), (2) mutations due to error-prone replication bypass of naturally occurring DNA damage (also called error-prone translesion synthesis), (3) errors introduced during DNA repair, and (4) induced mutations caused by mutagens. Scientists may sometimes deliberately introduce mutations into cells or research organisms for the sake of scientific experimentation. One 2017 study claimed that 66% of cancer-causing mutations are random, 29% are due to the environment (the studied population spanned 69 countries), and 5% are inherited. Humans on average pass 60 new mutations to their children but fathers pass more mutations depending on their age with every year adding two new mutations to a child.
Metrohm was founded in 1943 in Herisau by Bertold Suhner and Willi Studer. At the outset, the company produced measuring instruments for high-frequency technology and telecommunications. High-precision measuring instruments as well as radio receivers were added to its product range later on. After World War II, the company struggled as the demand for their products decreased, since it was cheaper to buy imported radios from the US. Thus, Suhner decided to venture into analytical chemistry and developed a first pH meter in 1947, followed by a titrator in 1949. In 1947, Suhner and Studer parted ways. Swiss journalist and author Peter Holenstein describes how this happened in his book on the lifework of co-founder Willi Studer: In June 1947, Emil Haefely, founder of the company Emil Haefely & Cie AG, which was one of Metrohm's first customers, asked Willi Studer, whom he had known for many years, to build a prototype for a cathode-ray oscilloscope. This being new technology for Metrohm, Bertold Suhner opposed the idea, fearing that the development wouldn't be possible within reasonable time and budget constraints. Indeed, while the development of the simpler instruments in Metrohm's portfolio had never taken Studer more than a few weeks, Studer still hadn't finished the prototype after several months at the end of November 1947. At this point, his colleague Suhner lost all hope that the project would come to a successful conclusion. A break between the co-founders was the result, and led Studer to leave the company at the end of December 1947.
Middleton is dyslexic. He read from the New Revised Standard Version of the Bible at the 2011 wedding of his sister Catherine to Prince William. In 2019, he disclosed his struggles with depression and attention deficit hyperactivity disorder, which he attributed to public scrutiny from age 23 as a result of his eldest sister's relationship. He sought treatment in 2017, undertaking cognitive behavioral therapy. Middleton also spent "restorative time" at the Glen Affric Estate, where he has hosted deer-stalking parties. The estate is owned by his sister Philippa's father-in-law. In the same year, he penned a column in the Daily Mail about mental health. Middleton is an ambassador for the Pets As Therapy charity and has credited his dog, Ella, for helping him through his depression. He breeds dogs, owning six, as well as one rescue lamb. Middleton also keeps bees on the grounds of Bucklebury Manor. In April 2020, he founded the Paw Print Fund in aid of animal welfare charities. Middleton was in a relationship with actress Donna Air from 2013 to 2018. Middleton met French financial analyst Alizée Thevenet (b. 30 November 1989) in 2018. She is the daughter of retired diplomat Jean-Gabriel Thevenet. Middleton and Alizée announced their engagement in September 2019. On 11th September 2021, Alizée's mother, along with James's family, attended the wedding in the village of Bormes-les-Mimosas in the south of France where Alizée's family lives. Alizée's father had died some months before the wedding.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.